These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16281428)

  • 1. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
    Berry DA
    Clin Trials; 2005; 2(4):295-300; discussion 301-4, 364-78. PubMed ID: 16281428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case for Bayesianism in clinical trials.
    Berry DA
    Stat Med; 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PubMed ID: 8248653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
    Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
    Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 10. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
    Adrion C; Mansmann U
    BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.
    Kpozèhouen A; Alioum A; Anglaret X; Van de Perre P; Chêne G; Salamon R
    Am J Epidemiol; 2005 Mar; 161(6):595-603. PubMed ID: 15746476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive probability of success using surrogate endpoints.
    Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
    Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Bayesian randomized trials: realizing their potential.
    Pullenayegum EM
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
    Guo B; Liu S
    Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.